Literature DB >> 16170179

Psychoactive medications and risk of delirium in hospitalized cancer patients.

Jean-David Gaudreau1, Pierre Gagnon, François Harel, Marc-André Roy, Annie Tremblay.   

Abstract

PURPOSE: Psychoactive medications are biologically plausible and potentially modifiable risk factors of delirium. To date, however, research findings are inconsistent regarding their association with delirium. The association between exposure to anticholinergics, benzodiazepines, corticosteroids, and opioids and the risk of delirium was studied. PATIENTS AND METHODS: A total of 261 hospitalized cancer patients were followed up with repeated assessments by using the Nursing Delirium Screening Scale for up to 4 weeks for incident delirium. Detailed exposure to psychoactive medications was documented daily. Strengths of association with delirium were expressed as hazard ratios (HRs) in univariate and multivariate analyses by using Cox regression models. All medication variables were coded as time-dependent covariates. Whenever possible, exposure was computed by using cumulative daily doses in equivalents; dichotomous cutoffs were determined.
RESULTS: During follow-up (mean, 8.6 days), 43 patients became delirious (16.5%). Delirium was associated with a history of delirium and the presence of hepatic metastases at admission. Analysis of the effect of medications was performed adjusting for these factors. Patients exposed to daily doses of benzodiazepines above 2 mg (HR, 2.04; 95% CI, 1.05 to 3.97), above 15 mg of corticosteroids (HR, 2.67; 95% CI, 1.18 to 6.03), or above 90 mg of opioids (HR, 2.12; 95% CI, 1.09 to 4.13) had increases in the risks for delirium. We did not observe associations between anticholinergics and risk for delirium.
CONCLUSION: Exposure to opioids, corticosteroids, and benzodiazepines is independently associated with an increased risk of delirium in hospitalized cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170179     DOI: 10.1200/JCO.2005.05.140

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

Review 2.  Incidence and associated factors of delirium after orthopedic surgery in elderly patients: a systematic review and meta-analysis.

Authors:  Yanjiang Yang; Xin Zhao; Lei Gao; Ying Wang; Juan Wang
Journal:  Aging Clin Exp Res       Date:  2020-08-09       Impact factor: 3.636

3.  Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation.

Authors:  Jesse R Fann; Rebecca A Hubbard; Catherine M Alfano; Sari Roth-Roemer; Wayne J Katon; Karen L Syrjala
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

Review 4.  Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.

Authors:  Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor
Journal:  J Pain Symptom Manage       Date:  2014-01-28       Impact factor: 3.612

5.  Impact of pneumonia on hyperactive delirium in end-stage lung cancer patients.

Authors:  Hidekazu Suzuki; Tomonori Hirashima; Masashi Kobayashi; Norio Okamoto; Yuka Matsuura; Motohiro Tamiya; Naoko Morishita; Kohei Okafuji; Takayuki Shiroyama; Osamu Morimura; Satomu Morita; Ichiro Kawase
Journal:  Support Care Cancer       Date:  2012-06-19       Impact factor: 3.603

Review 6.  Evidence-based treatment of delirium in patients with cancer.

Authors:  William Breitbart; Yesne Alici
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

Review 7.  Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practice.

Authors:  Scott A Irwin; Rosene D Pirrello; Jeremy M Hirst; Gary T Buckholz; Frank D Ferris
Journal:  J Palliat Med       Date:  2013-03-12       Impact factor: 2.947

Review 8.  Delirium in patients with cancer: assessment, impact, mechanisms and management.

Authors:  Peter G Lawlor; Shirley H Bush
Journal:  Nat Rev Clin Oncol       Date:  2014-09-02       Impact factor: 66.675

9.  An analytical framework for delirium research in palliative care settings: integrated epidemiologic, clinician-researcher, and knowledge user perspectives.

Authors:  Peter G Lawlor; Daniel H J Davis; Mohammed Ansari; Annmarie Hosie; Salmaan Kanji; Franco Momoli; Shirley H Bush; Sharon Watanabe; David C Currow; Bruno Gagnon; Meera Agar; Eduardo Bruera; David J Meagher; Sophia E J A de Rooij; Dimitrios Adamis; Augusto Caraceni; Katie Marchington; David J Stewart
Journal:  J Pain Symptom Manage       Date:  2014-04-12       Impact factor: 3.612

10.  Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.

Authors:  Ahmed Elsayem; Eardie Curry Iii; Jeanette Boohene; Mark F Munsell; Bianca Calderon; Frank Hung; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2008-05-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.